Novavax, Inc. (NVAX) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Company performance

Current Price

as of Jan 23, 2025

$9.55

P/E Ratio

N/A

Market Cap

$1.53B

Description

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Metrics

Overview

HQGaithersburg, MD
SectorHealth Technology
IndustryBiotechnology
TickerNVAX
Price$9.55+8.15%

Trading Information

Market cap$1.53B
Float95.51%
Average Daily Volume (1m)4,753,649
Average Daily Volume (3m)4,688,348
EPS-$2.16

Company

Revenue$885.19M
Rev growth (1yr)-54.80%
Net income-$121.30M
Gross margin30.40%
EBITDA margin-138.53%
EBITDA-$117.07M

EV$1.33B
EV/Revenue1.51
P/EN/A
P/S1.73
P/BN/A

Documents

Factset Street Account

StreetAccount Earnings Call Q&A Summary: Novavax, Inc. Q3 ($6.83, +0.03) (2023-11-09T18:42:09Z)

Novavax's updated protein-based COVID-19 vaccine now an option for all 194 member states of the WHO ($5.46, 0.00) (2023-11-28T11:03:23Z)

Novavax's COVID-19 vaccine Nuvaxovid receives full approval in Singapore ($6.45, 0.00) (2023-10-18T12:04:34Z)

Novavax, Inc. reports Q3 GAAP EPS ($1.26) vs year-ago ($2.15) - 10-Q ($6.80, 0.00) (2023-11-09T12:37:11Z)

Novavax, Inc. issues press release on Q3 results; reports Q3 GAAP EPS ($1.26) vs FactSet ($1.80) [6 est, ($2.71)-0.28]; prepares to initiate cost reduction program ($6.80, 0.00) (2023-11-09T14:07:35Z)

Novavax receives full marketing authorization for prototype COVID-19 vaccine Nuvaxovid ▼ in United Kingdom ($6.45, 0.00) (2023-10-18T12:08:16Z)

Novavax finalizes agreements with pharmacy retailers and GPOs to provide the company's Covid-19 vaccine ($7.45, 0.00) (2023-10-13T13:33:32Z)

Novavax comments on WHO's recommendation of R21/Matrix-M malaria vaccine ($7.17, -0.07) (2023-10-02T17:07:59Z)

Novavax appoints John Trizzino to newly created role of President and COO ($5.83, 0.00) (2023-11-17T12:17:26Z)

Follow-up: FDA amends EUA for Novavax's COVID-19 vaccine to include 2023-2024 formula ($6.84, -0.25) (2023-10-03T18:44:13Z)

CORRECTION: Novavax, Inc. guides FY revenue $900M-$1.10B vs prior guidance $1.30-1.50B and FactSet $1.37B [6 est, $1.35-1.40B] ($6.80, 0.00) (2023-11-09T14:11:02Z)

Earnings Calls

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report 2023Q4

Earnings Report (2023-11-09)

Earnings Report (2023-08-08)

Factset

Factset Business Description

Wikipedia

Novavax,_Inc.